Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.02+0.32 (+11.85%)
Close on Nov 13, 2026Market cap $313.73MP/E –Yield –
Larimar Therapeutics cash
Cash and short-term investments held at the end of each period.
Larimar Therapeutics's cash was $156.30M at Jun 30, 2026. For fiscal 2025 it was $136.90M, down 25.4% from the year before. Over ten years it grew -3.0% a year on average. The highest annual figure on record is $185.08M in fiscal 2015.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.90M | -25.4% |
| FY2024 | Dec 31, 2024 | $183.50M | +111.4% |
| FY2023 | Dec 31, 2023 | $86.80M | -26.7% |
| FY2022 | Dec 31, 2022 | $118.40M | +68.9% |
| FY2021 | Dec 31, 2021 | $70.10M | -24.3% |
| FY2020 | Dec 31, 2020 | $92.64M | +31.8% |
| FY2019 | Dec 31, 2019 | $70.30M | -40.5% |
| FY2018 | Dec 31, 2018 | $118.10M | +15.7% |
| FY2017 | Dec 31, 2017 | $102.10M | -21.0% |
| FY2016 | Dec 31, 2016 | $129.20M | -30.2% |
| FY2015 | Dec 31, 2015 | $185.08M | +60.3% |
| FY2014 | Dec 31, 2014 | $115.46M | +225.1% |
| FY2013 | Dec 31, 2013 | $35.52M | +257.5% |
| FY2012 | Dec 31, 2012 | $9.94M | +577.2% |
| FY2011 | Dec 31, 2011 | $1.47M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $156.30M | +12.9% |
| Q1 FY2026 | Mar 31, 2026 | $200.40M | +27.2% |
| Q4 FY2025 | Dec 31, 2025 | $136.90M | -25.4% |
| Q3 FY2025 | Sep 30, 2025 | $175.40M | -13.9% |
| Q2 FY2025 | Jun 30, 2025 | $138.50M | -38.7% |
| Q1 FY2025 | Mar 31, 2025 | $157.50M | -34.1% |
| Q4 FY2024 | Dec 31, 2024 | $183.50M | +111.4% |
| Q3 FY2024 | Sep 30, 2024 | $203.70M | +113.1% |
| Q2 FY2024 | Jun 30, 2024 | $226.10M | +117.0% |
| Q1 FY2024 | Mar 31, 2024 | $239.00M | +114.3% |
| Q4 FY2023 | Dec 31, 2023 | $86.80M | -26.7% |
| Q3 FY2023 | Sep 30, 2023 | $95.60M | -23.3% |
| Q2 FY2023 | Jun 30, 2023 | $104.20M | +89.8% |
| Q1 FY2023 | Mar 31, 2023 | $111.52M | +78.3% |
| Q4 FY2022 | Dec 31, 2022 | $118.40M | +68.9% |
| Q3 FY2022 | Sep 30, 2022 | $124.70M | +59.8% |
| Q2 FY2022 | Jun 30, 2022 | $54.90M | -22.3% |
| Q1 FY2022 | Mar 31, 2022 | $62.56M | -23.2% |
| Q4 FY2021 | Dec 31, 2021 | $70.10M | -24.3% |
| Q3 FY2021 | Sep 30, 2021 | $78.02M | -23.7% |
| Q2 FY2021 | Jun 30, 2021 | $70.63M | -37.9% |
| Q1 FY2021 | Mar 31, 2021 | $81.44M | +27.4% |
| Q4 FY2020 | Dec 31, 2020 | $92.64M | +31.8% |
| Q3 FY2020 | Sep 30, 2020 | $102.31M | +24.8% |
| Q2 FY2020 | Jun 30, 2020 | $113.68M | +24.0% |
| Q1 FY2020 | Mar 31, 2020 | $63.90M | -39.0% |
| Q4 FY2019 | Dec 31, 2019 | $70.30M | -40.5% |
| Q3 FY2019 | Sep 30, 2019 | $82.00M | -35.8% |
| Q2 FY2019 | Jun 30, 2019 | $91.70M | +21.0% |
| Q1 FY2019 | Mar 31, 2019 | $104.70M | +17.5% |
| Q4 FY2018 | Dec 31, 2018 | $118.10M | +15.7% |
| Q3 FY2018 | Sep 30, 2018 | $127.80M | +37.2% |
| Q2 FY2018 | Jun 30, 2018 | $75.80M | -28.5% |
| Q1 FY2018 | Mar 31, 2018 | $89.10M | -23.8% |
| Q4 FY2017 | Dec 31, 2017 | $102.10M | -21.0% |
| Q3 FY2017 | Sep 30, 2017 | $93.18M | -32.8% |
| Q2 FY2017 | Jun 30, 2017 | $106.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $116.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $129.20M | – |
| Q3 FY2016 | Sep 30, 2016 | $138.66M | – |
See a number that looks wrong?